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B7-H4, a Molecule of the B7 Family,
Negatively Regulates T Cell Immunity
a putative negative signal (Chambers et al., 2001). Ma-
nipulation of this pathway has profound effects on both
humoral and cell-mediated immune responses. For ex-
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mune diseases and transplantation rejection (SalomonRochester, Minnesota 55905
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cell specific transcripts (Tseng et al., 2001). Both B7-H1
and B7-DC are capable of binding to programmed death
1 (PD-1) receptor (Freeman et al., 2000, Latchman etSummary
al., 2001). PD-1-deficient mice spontaneously develop
systemic and organ-specific autoimmune diseases (Ni-We identify a B7 family molecule, B7-H4, by protein
shimura et al., 1999), strongly supporting a role of PD-1sequence analysis and comparative molecular model-
in negative regulation of T cell responses. While bothing. While B7-H4 mRNA is widely distributed in mouse
B7-H1 and B7-DC were found to be costimulatory forand human peripheral tissues, cell surface expression
naive T cells (Dong et al., 1999; Tseng et al., 2001), otherof B7-H4 protein is limited and shows an inducible
laboratories showed that B7-H1 and B7-DC inhibitedpattern on hematopoietic cells. Putative receptor of
proliferation of activated T cells (Freeman et al., 2000;B7-H4 can be upregulated on activated T cells. By
Latchman et al., 2001). Because it was proposed thatarresting cell cycle, B7-H4 ligation of T cells has a
both B7-H1 and B7-DC functioned through PD-1, theseprofound inhibitory effect on the growth, cytokine se-
molecules were renamed as PD-L1 and PD-L2, respec-cretion, and development of cytotoxicity. Administra-
tively, to reflect this association (Freeman et al., 2000;tion of B7-H4Ig into mice impairs antigen-specific
Latchman et al., 2001), This hypothesis, however, failsT cell responses whereas blockade of endogenous B7-
to integrate all experimental findings. T cell costimula-H4 by specific monoclonal antibody promotes T cell
tion by B7-H1 is likely mediated through a different re-responses. B7-H4 thus may participate in negative
ceptor (Dong et al., 2002). This is best indicated by theregulation of cell-mediated immunity in peripheral
fact that mutants of B7-H1 and B7-DC, which lose theirtissues.
ability to bind PD-1, remain costimulatory for T cells
(Wang et al., 2003), and both B7-H1 and B7-DC canIntroduction
costimulate PD-1/ T cells (Wang et al., 2003; Shin et
al., 2003). Importantly, B7-H1 expresses constitutively
B7-like molecules belong to the immunoglobulin (Ig) su- on the majority of human cancers (Dong et al., 2002)
perfamily. Based on amino acid sequence and protein and some mouse tumor lines (Iwai et al., 2002), promotes
structure analysis, B7-like molecules can be distin- apoptosis of activated human T cells (Dong et al., 2002),
guished from other members within an extended B7 and renders resistance of mouse tumors to T cell attack
family (Linsley et al., 1994). The extracellular portion of (Dong et al., 2002; Iwai et al., 2002).
B7-like molecules contain single IgV and IgC domains B7h/B7RP-1 (B7-H2, GL-50, ICOS ligand, LICOS) was
and share 20%–40% amino acid identity. Upon bind- independently identified by at least six laboratories (Car-
ing to their counterreceptors on T cells, B7-like mole- reno and Collins, 2002). Considerable interest was
cules play critical roles in the control and fine tuning of raised when mouse (Yoshinaga et al., 1999; Mages et
antigen-specific immune responses. Interactions be- al., 2000) and human (Wang et al., 2000; Ling et al., 2000)
tween B7-1 (CD80)/B7-2 (CD86) ligands to CD28/CTLA-4 receptor for B7h/B7RP-1 was identified as the inducible
(CD152) receptors represent a classical pathway. B7s costimulator (ICOS) (Hutloff et al., 1999). Molecular mod-
costimulate growth, prevent anergy, and promote sur- eling demonstrates that ICOS has a structure similar to
vival of T cells via CD28 receptor. Binding of B7s to CD28 (Wang et al., 2002) and is expressed primarily on
CTLA-4, however, inhibits T cell responses by delivering the surface of activated T cells and resting memory
T cells (Hutloff et al., 1999). Interaction of ICOS and B7h/
B7RP-1 plays critical roles in the regulation of T helper-*Correspondence: chen.lieping@mayo.edu
5These authors contributed equally to this work. dependent antibody production, Th1 and Th2 cytokine
Immunity
850
Figure 1. Sequence Analysis and Molecular Models of B7-H4
(A) Amino acid alignment of mouse and human B7-H4. Gray shading indicates amino acid identity. , signal peptide; , transmembrane
domain. Alignment was performed with ClustalW algorithm in MacVector 6.5.
(B) Amino acid comparison of human B7-H4 with the B7 family molecules. Only extracellular domains without signal peptides were compared.
IgV domain, … ; IgC doman, . The asterisks indicate conserved cysteines important for intrachain disulfide bonds. Dark gray indicates amino
acid identity. Light gray indicates amino acid similarity. Comparisons have been done with ClustalW algorithm in MacVector 6.5.
(C) Structure-oriented sequence alignment. Shown is an alignment of the sequences of the IgV domains of human and mouse B7-H4 relative
to human CD80 and CD86. This alignment is based on superposition of CD80 and CD86 and the conservation of structural key residues of
the IgV-fold.  strands seen in CD80 and CD86 are labeled according to Ig superfamily conventions (A-G). Residue positions that are
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secretion, and cell-mediated immune responses in Structure Analysis of B7-H4
B7-H4 has only about 25% amino acid homology inmouse models (Carreno and Collins, 2002). Recent stud-
ies in the patients with common variable immunodefi- the extracellular portion with other B7 family members
(Figure 1B). Intrachain disulfide bond formed by cys-ciency, however, indicate that homozygous loss of ICOS
does not lead to defective T cell responses, although B teines are all conserved between B7-H4 and the other
B7 family members. Since the IgV domain of the B7cell responses were compromised (Grimbacher et al.,
2003). More recently, a new B7-like molecule, B7-H3, family is primarily involved in the binding with the count-
erreceptor (Stamper et al., 2001; Schwartz et al., 2001),has been identified (Chapoval et al., 2001). B7-H3 co-
stimulates T cell proliferation, selectively induces IFN-, we analyzed the IgV domain of human and mouse B7-H4
by computer modeling. Figure 1C shows the structure-and promotes growth and differentiation of CD8 CTL
against allogeneic antigens, indicating that B7-H3 may based V domain sequence alignment on which CD86
was used as the template. The V domain regions ofpreferentially costimulate the cellular immune response.
In this report, we describe B7-H4, a B7-like molecule human and mouse B7-H4 are highly homologous (91%
sequence identity), whereas this region in B7-H4 shareswith profound inhibitory function for T cell responses.
only23% sequence identity with both CD80 and CD86.
In CD80 and CD86, the V domains contain the CTLA-4/
CD28 binding site, and the binding site region is largelyResults
conserved in these molecules and maps to the
AGFCCC″ face (Figure 1D). In addition, correspondingCloning and Sequence Analysis of B7-H4
When a human expressed sequence tagged (EST) data- regions adjacent to but distinct from the receptor bind-
ing site mediate homodimerization of CD80 and CD86base was queried with sequences of the IgV and IgC
domains of the B7 family molecules, a partial EST se- (Figures 1C and 1D). We have generated molecular mod-
els of human (Figure 1D) and mouse B7-H4 (data notquence was identified. Subsequent searching of the da-
tabase with the partial fragment led to additional EST shown) in three dimensions relative to CD80/CD86.
Many core or Ig superfamily consensus residue posi-sequences that overlapped the initial fragment. Using
this strategy, a nucleotide sequence encoding the full- tions are conserved, or conservatively replaced, in
CD80/CD86 and B7-H4, leaving little doubt that thelength B7-H4 was identified and cloned using placenta
cDNA as a template. The hB7-H4 sequence encodes a structures of these molecules are similar overall. Essen-
tially no residues conserved in CD80/CD86 and B7-H4putative protein of 282 amino acids with several poten-
tial N-glycosylation sites in the extracellular domain. The map to the AGFCCC″ face of B7-H4, thus predicting
that B7-H4 does not bind CTLA-4 or CD28. Furthermore,amino acid sequence of hB7-H4 contains a large hy-
drophobic transmembrane domain and a very short in- only a few residues that differ in human and mouse B7-
H4 map to the surface of their V domain (colored goldtracellular domain comprised of only 2 amino acids (Fig-
ure 1A). Predicted hB7-H4 is a type I transmembrane in Figure 1D), including the region that spatially corre-
sponds to the receptor binding site in CD80/CD86 onprotein.
A BLAST search of the NCBI databases with hB7-H4 the AGFCCC″ face. This suggests that human and
mouse B7-H4 are likely to display cross-species recep-sequence revealed a partial EST sequence correspond-
ing to the 5 sequence of the mouse B7-H4 (mB7-H4) tor binding.
ortholog (accession number AI155439). Using a primer
designed from this partial EST sequence and several Expression Pattern of B7-H4
Northern blot analysis of B7-H4 indicates that hB7-H4primers derived from the 3 end of the hB7-H4 sequence,
a PCR fragment containing the entire mouse B7-H4 se- mRNA is expressed in spleen, lung, and thymus. The
most prominent transcript for B7-H4 is approximatelyquence was obtained from mouse spleen cDNA. The
mouse and human amino acid sequences have approxi- 1.8 kb (Figure 2A). By sensitive RT-PCR analysis, B7-H4
mRNA is also found in placenta, liver, skeletal muscle,mately 87% amino acid identity (Figure 1A). The level
of identity between the mouse and human orthologs kidney, pancreas, prostate, testis, ovary, and small in-
testine (Figure 2B). Immunohistochemistry analysis us-suggests that this molecule is highly conserved evolu-
tionarily. ing a human B7-H4 specific mAb (hH4), however, does
conserved, or mostly conserved, in the compared sequence are shaded. Among these, the most important IgV-fold consensus residue
positions (important for maintaining structural integrity) are labeled with asterisks. Potential N-linked glycosylation sites are boxed. Residue
positions labeled with # participate in the formation of the homodimer interface seen in the X-ray structure of CD86 in complex with CTLA-4.
CD86 residues that participate in CTLA-4 binding are labeled with exclamation marks and used for binding site mapping in (D). Residue
numbers are given for human B7-H4.
(D) Mapping of conserved residues. The V domain of the X-ray structure of hCD86 (light blue) and the molecular model of hB7-H4 (white) are
displayed with molecular surfaces and shown in two orientations. The top view focuses on the BED -sheet surface of the domains and the
bottom on the opposing AGFCCC″ surface (related by 180 rotation around the vertical axis). CD86 residues important for CTLA-4 binding
are colored red (bottom left), and those residues that delineate the homodimerization region in CD80 and CD86, as seen in their crystal
structures with CTLA-4, are shown in magenta (top left). In contrast to the receptor binding site, the dimer interface maps to the BED face
of the domain. For residues involved in CTLA-4/CD28 binding and dimerization, see also (C). In the middle images, residues that are identical
in hCD80 and hCD86 are colored dark blue. On the right, residues that are conserved in CD80, CD86, and B7-H4 are also colored dark blue.
In addition, residues that are different in human and mouse B7-H4 are shown in gold. As can be seen, only a few nonconserved residue
positions map to the surface of B7-H4.
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Figure 2. Expression and Putative Receptor of B7-H4
(A) Northern blot of hB7-H4 mRNA using human multiple tissue panels.
(B) PCR analysis of hB7-H4 expression using human multiple cDNA panels.
(C) FACS analysis of B7-H4 expression on the human B cells, T cells, monocytes, and DC stimulated with LPS, PHA, IFN-, PMA, or ionomycin
for 3 days. Cells were stained with hH4 mAb.
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not reveal positive staining for B7-H4 in all organs from transfected with B7-1, B7-H2, and B7-H1, respectively
(Figure 2J). Our data indicates that B7-H4 binds to anormal individuals, including lung, colon, liver, skeletal
muscle, kidney, pancreas, small bowel, breast, and receptor on activated T cells, which is distinct from
CTLA-4, ICOS, or PD-1.uterus (data not shown). Likewise, freshly isolated hu-
man T cells, B cells, monocytes, and DC do not express
B7-H4 on cell surface in FACS analysis. In contrast, Inhibition of T Cell Responses by B7-H4 In Vitro
Using immobilized anti-CD3 mAb as antigen mimic, weB7-H4 expression can be induced on T cells, B cells,
monocytes, and DC after in vitro stimulation (Figure 2C). tested the effect of B7-H4 ligation on T cell responses.
Stimulation by an anti-CD3 mAb on freshly purified, na-Monocyte-derived DCs do not contain a transcript for
B7-H4 while these DC express B7-H4 after stimulation ive CD4 T cells from DO11.10 TCR transgenic mice
led to the proliferation of T cells in a dose-dependentwith PMA and ionomycin. Human aortic endothelial cells
do not express B7-H4, even after TNF (Figure 2D) and fashion. Inclusion of immobilized mB7-H4Ig but not con-
trol Ig in the beginning of the cultures significantly inhib-IFN- (data not shown) stimulation by both FACS and
RT-PCR analysis. Probing of a mouse tissue Northern ited T cell proliferation. Inclusion of immobilized B7-
H4Ig did not affect the binding of anti-CD3 mAb onblot indicated that mB7-H4 has up to four different
mRNA transcripts, depending on the tissue type. The plastic plate (data not shown), thus excluding a nonspe-
cific effect of B7-H4Ig. In the identical setting, immobi-liver has both the highest level of B7-H4 and all four
transcripts, varying in size from 7.5, 4, 2.6, and 1.8 kb lized B7-1Ig costimulated the growth of T cells (Figure
3A). Soluble mB7-H4Ig up to 20 	g/ml did not have an(Figure 2E). Mouse B7-H4 transcript was detected in the
heart, lung, liver, skeletal muscle, kidneys, and testis inhibitory effect in this assay (data not shown), which
excludes the possibility of nonspecific cytotoxicity ofbut not in brain and spleen. RT-PCR analysis, however,
demonstrates the mRNA in all these organs (Figure 2F). B7-H4Ig and also suggests that crosslinking of B7-H4
is required for its inhibitory effect. Similarly, dose-Detection of high level B7-H4 mRNA in liver is likely due
to constitutive level of the RNA in hepatocyte because dependent inhibition by B7-H4Ig was also observed us-
ing purified CD4 T cells from B6 mice (Figure 3B). Toall lymphocytes isolated from liver were negative by RT-
PCR (data not shown). examine the effect of B7-H4Ig ligation on the production
of cytokines, culture supernatants from DO11.10 T cell
proliferation assays as shown previously were harvestedInducible Expression on T Cells of B7-H4
Putative Receptor at 24, 48, and 72 hr, and the secretion of IL-2 (Figure
3C) and IL-10 (Figure 3D) was examined. There is eitherTo test whether T cells express B7-H4 receptor, we first
constructed vectors to express fusion proteins con- a low level or no production of IL-2 and IL-10 at 24 hr
whereas these cytokines can be detected in high levelssisting of the extracellular domain of human or mouse
B7-H4 fused to the Fc portion of mouse IgG2a or human at 48 or 72 hr by anti-CD3 mAb stimulation in the pres-
ence of control Ig. Inclusion of B7-H4Ig significantlyIgG1, respectively (Chapoval et al., 2002). The purified
recombinant fusion proteins were used to detect the inhibited the production of IL-2 and IL-10 at these time
points.presence of a putative B7-H4 receptor on T cells via
FACS analysis. Although hB7-H4Ig did not bind freshly Although it does not inhibit proliferation of T cell re-
sponse, soluble B7-H4Ig could partially suppress theisolated human T cells (data not shown), 20%–30% of
T cells upon stimulation with anti-CD3 mAb were stained generation of allogeneic cytolytic T cells (CTL) in vitro.
When purified B6 T cells were stimulated in vitro withpositive (Figure 2G). This result suggests that activated
human T cells express a putative receptor for B7-H4. irradiated spleen cells of BDF1 origin, high levels of
cytolytic activity were generated against P815 cellsTo determine whether B7-H4 binds to other B7 recep-
tors, we first established 293T transfectants expressing (H-2d). The induction of allogeneic CTL activity in this
system was partially inhibited by inclusion of B7-H4IghB7-H4 (hB7-H4.293T) or mB7-H4 (mB7-H4.293T) and
examined the binding of CTLA-4Ig, ICOSIg, and PD-1Ig in the beginning of the cultures (Figure 3E). Our results
indicate that soluble B7-H4Ig could inhibit, at least into these cells by FACS. Expression of B7-H4 on B7-H4-
transfected, but not mock-transfected, 293 cells was part, induction of allogeneic CTL in vitro.
B7-CD28 costimulation represents an early activationconfirmed by mAb specific for either mouse or human
B7-H4 (Figure 2H). In FACS analysis, CTLA4Ig, ICOSIg, signal for optimal T cell proliferation. To determine
whether B7-H4 inhibits CD28 costimulation, we includedand PD-1Ig did not bind B7-H4 transfectants (Figure 2I),
although these Ig fusion proteins are able to bind cells B7-H4Ig in the beginning of DO11.10 T cell cultures that
(D) RT-PCR analysis of human B7-H4 mRNA from (1) PBMC, (2) plastic nonadherent PBMC, (3) dendritic cells, (4) dendritic cells stimulated
with PMA and ionomycin, (5) human aortic endothelium (HAEL), and (6) HAEL stimulated with TNF-.
(E) Northern blot of mB7-H4 mRNA using mouse multiple tissue panels. Each line contains 1 	g of poly (A) RNA. Molecular size markers are
indicated in kb. Human and mouse full-length B7-H4 cDNA were used as probes for respective tissue panels.
(F) PCR analysis of mouse cDNA from multiple tissues with mB7-H4-specific primers.
(G) Human T cells stimulated with anti-CD3 mAb at 5 	g/ml for 44 and 68 hr, stained with control human IgG (shaded) or B7-H4Ig (open) and
subjected to FACS analysis.
(H) Expression of B7-H4 by 293 transfectants. 293T cells expressing human B7-H4 (hB7-H4.293T) or mouse B7-H4 (mB7-H4.293T) were stained
by hH4 mAb for human B7-H4 or 8H4 for mouse B7-H4.
(I) FACS analysis of mB7-H4.293T line with mCTLA4 Ig and mPD-1Ig, and hB7-H4.293T line with hICOSIg.
(J) Positive control staining of mCTLA4Ig for mB7-1.P815 line, mPD-1Ig for mB7-H1.P815 line, and hICOSIg for hB7-H2.CHO line.
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Figure 3. B7-H4 Inhibits Anti-CD3-Induced T
Cell Proliferation and Cytokine Production
(A and B) Anti-CD3 mAb was plate coated at
5 	g/ml except when indicated at 4C over-
night. The plates were washed three times
with PBS and coated with 10 	g/ml (A) or
with the indicated concentration of the fusion
protein (B) for 2 hr at 37C. Wells were washed
three times with PBS, and cells were plated
at a density of 1.5 
 106 cells/ml (200 	l).
Cells were pulsed with 1 	Ci of [3H]thymidine
and harvested at 72 hr after stimulation.
T cells were purified from DO11.10 (A) or B6
mice (B) by a CD4 magnetic selection column.
These data are representative of three inde-
pendent experiments.
(C–E) Supernatants from DO11.10 cells stim-
ulated with 3 	g/ml anti-CD3 mAb and 10 	g/
ml of B7-H4Ig (solid bars) or control Ig (open
bars) were harvested at the indicated time
points. Sandwich ELISA for IL-2 (C) and IL-
10 (D) were performed at the same time for
all time points. To determine the role of solu-
ble B7-H4Ig in the generation of alloreactive
CTL, purified T cells from B6 mice were stimu-
lated with -irradiated BDF1 spleen cells at
a ratio of 1:3 in the presence of 10 	g mB7-
H4Ig or control Ig for 4 days. T cells were
purified by LymphoLyte M and used at indi-
cated effector:target (E:T) ratios against P815
cells in a 4 hr 51Cr-release assay (E). All assays
were done with triplicated wells. These data
are representative of at least two indepen-
dent experiments.
were exposed to anti-CD3 mAb and B7-1Ig. While B7- TCR transgenic T cells with mock.EL4 cells which were
incubated with a H-2Kb-restricted OVA peptide1Ig costimulates a much higher level of proliferation and
IL-2 secretion in the presence of anti-CD3, compared (mock.EL4/) led to strong proliferation of OT-1 cells
while mock.EL4 cells without the peptide sensitizationwith anti-CD3 mAb alone (Figures 3A and 3C), inclusion
of B7-H4Ig significantly inhibited both T cell proliferation (mock.EL4/) did not, indicating that proliferation of OT-1
cells is specific for OVA peptide. Importantly, the stimu-and IL-2 production (Figure 4A). Using nylon-wool puri-
fied polyclonal T cells from B6 mice, we further demon- lation by the peptide-pulsed EmH4 cells (EmH4/) in-
duced significantly decreased proliferation in compari-strated the inhibition by B7-H4Ig of IL-2, IL-4, IL-10, and
IFN- secretion from B7-1 costimulated T cells (Figure son with mock.EL4/ cells (Figure 5B) and inhibited
cytolytic activity against OVA-positive EG7 cells (Figure4B). Our results thus indicate that B7-H4-induced inhibi-
tion of T cell proliferation could not be reversed by CD28 5C). The inhibitory effect of B7-H4 on EL4 cells could
be largely neutralized by the inclusion of 8H4 and 8H4.1costimulation.
We next examined whether B7-H4 on cell surface also mAbs (Figure 5D). Our results indicate that, in addition
to crosslinking of B7-H4, cell-associated B7-H4 couldinhibits T cell responses. To test this, we transfected
EL4 cells with the mB7-H4 cDNA plasmid to establish also inhibit T cell response.
a line that stably expresses B7-H4 (EmH4). As shown
in Figure 5A, EmH4 expresses a high level of mouse B7- Cell Cycle Arrest by B7-H4
Extensive inhibitory effect by B7-H4 in T cell proliferationH4 on the surface by FACS using 8H4 mAb whereas
mock.EL4 does not. Both mock.EL4 and EmH4 express and cytokine production suggests that B7-H4 may in-
hibit cell division and even arrest cell cycle. To test thesesimilar levels of H-2Kb and H-2Db. Stimulation of OT-1
Immune Inhibitory Functions of B7-H4
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Figure 4. B7-H4 Inhibits CD28 Costimulation
CD4 DO11.10 (A) or purified T cells from B6
mice (B) were stimulated for 48 hr (A) or the
indicated times (B) prior to harvest. 96-well
plates were coated with the indicated con-
centrations of anti-CD3 mAb in PBS overnight
at 4C, washed three times in PBS, and
coated with the indicated recombinant pro-
tein cocktails, with each protein at 10 	g/ml,
for 2 hr at 37C. Wells were washed three
times with PBS and plated with 200 	l of puri-
fied DO11.10 cells (A) or purified T cells from
B6 mice (B) at a concentration of 1.5 
 106
cells/ml. Cells were pulsed overnight with 1
	Ci of [3H] thymidine 18 hr prior to harvesting.
Supernatants were harvested at the indicated
time points for cytokine ELISA. T cells were
purified from DO11.10 mice by a CD4 mag-
netic selection column or from B6 mice by
nylon wool column. These data are represen-
tative of at least two independent experi-
ments.
possibilities, purified T cells were labeled with CFSE, proliferation. Our results thus indicate that B7-H4 arrests
cell cycle progression of T cells in G0/G1 phase.incubated with immobilized anti-CD3 mAb and B7-H4Ig,
and subsequently analyzed by flow cytometry. Stimula-
tion of T cells by anti-CD3 mAb induced modest cell Inhibition of T Cell Responses by B7-H4 In Vivo
To evaluate the effect of B7-H4 on the inhibition of T cell-division (7.6%) at 48 hr, and nearly 70% of cells had more
than four cell divisions at 96 hr. Significant inhibitions of mediated immune responses in vivo, we transferred OT-1
cells into B6 mice to facilitate the tracing of T cell re-cell division were observed from 48 to 96 hr after expo-
sure to B7-H4Ig, as assessed by the lower percentage sponses. As a result of the transfer, 5%–7% of CD8
T cells in recipient spleens have OVA tetramer reactivity.of cells in the dividing peaks and decreased number of
peaks (Figure 6A). To precisely determine the effect of OT-1 T cells proliferate rigorously at day 6 upon immuni-
zation by OVA peptide (from 4.9% to 21.7%). Administra-B7-H4 on cell cycle, we labeled the purified T cells with
BrdU and 7-AAD for the analysis of cell cycle progres- tion of B7-H4Ig induced a moderate but significant de-
crease of OT-1 cells from 21.7% to 14.2% in spleenssion and apoptosis. As shown in Figure 6B, inclusion of
B7-H4Ig significantly decreased the cell numbers in S (Figure 7A). Our results thus indicate that administration
of B7-H4Ig could inhibit T cell proliferation in vivo.phase (from 54.9% to 25.0%) while the cell numbers
in G0/G1 phase increased (from 41.8% to 72.7%), in The effect of B7-H4Ig on the inhibition of alloreactive
CTL activity was also evaluated in vivo. As shown pre-comparison to that treated with control Ig. The apoptotic
cells, as determined by subdiploid population that viously, transfer of B6 spleen cells into sublethally irradi-
ated BDF1 (B6 x DBA/2) mice induced a rapid expansionshowed negative staining of 7-AAD, did not increase
significantly, indicating that programmed cell death is and increased cytolytic activity of anti-H-2d CD8 CTL,
which ultimately leads to death of the mice due to severenot a major mechanism responsible for inhibited T cell
Immunity
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Figure 5. Cell Surface B7-H4 in the Inhibition of T Cell Responses
(A) Mock-transfected EL4 (mock.EL4) or B7-H4 transfected EL4 (EmH4) cells were stained with control hamster IgG (shaded line) or 8H4 (gray
line) and analyzed by flow cytometry for the expression of mouse B7-H4, as shown in the two left panels. The staining of H-2Db and H-2Kb
molecules on mock.EL4 (gray line) and EmH4 cells (dark line) was also similarly determined by specific mAb to each MHC molecule using
flow cytometry. Shaded peak represents staining with isotype-matched control mAb for both mock.EL4 and EmH4 as shown in the two right
panels.
(B) Mock.EL4 or EmH4 cells were -irradiated and further incubated with 10 	g/ml of control peptide (mock.EL4/ and EmH4/) or SIIN
peptide (mock.EL4/ and EmH4/) overnight at 37C. The SIIN peptide-pulsed cells at 6 
 104/well were cocultured with 3 
 105 OT-1 T cells/
well at triplets in 96-well plates. Seventy-two hours later, the wells were pulsed with 1 	Ci of [3H]thymidine (TdR) for 18 hr.
(C) Purified OT-1 cells at 1.5 
 106/well were stimulated with either mock.EL4 or EmH4, which were pulsed with the SIIN peptide as described
in (B), for 4 days in 24-well plates. At the end of the culture, OT-1 cells were purified, and their cytolytic activity against 51Cr-labeled EG7 cells
was examined in a standard 4 hr 51Cr release assay at the indicated effector:target ratios.
(D) Purified OT-1 cells at 1.5 
 106/well were stimulated with OVA peptide-pulsed EmH4 together with 30 	g of anti-B7-H4 mAb from two
different clones (8H4 or 8H4.1) or hamster IgG for 3 days, and the proliferation was determined as described in (B).
graft versus host diseases (GVHD) accompanied with 7B). In addition, infusion of B7-H4Ig also extended the
survival of the mice undergoing GVHD (data not shown).failure of multiple organs (Tamada et al., 2000, 2002).
The recipients were treated with B7-H4Ig, and alloreac- Our results further indicate that B7-H4Ig could inhibit
the proliferation and maturation of CD8 CTL.tive CTL activity of spleen cells was directly examined
at day 10 without further in vitro stimulation. Treatment The role of endogenous B7-H4 in the generation of
allogeneic CTL was also accessed in vivo. After transferby B7-H4Ig significantly reduced CTL activity against
P815 (H-2d) in comparison with control Ig. CTL activity of B6 spleen cells into F1 mice, the recipients were
treated every other day with 8H4 mAb to block B7-H4.was specific for H-2d because the same CTL had only
minimal cytotoxicity against syngeneic EL4 cells (Figure In all three experiments, the treatment by 8H4 increased
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Figure 6. B7-H4 Induces Cell Cycle Arrest
(A) Nylon wool-purified naive CD4 T cells
(6 
 106/ml) from BALB/c mice were labeled
with CFSE (1 	M) and cultured in the anti-
CD3 (3 	g/ml) coated 96-well plates in the
presence of coated control IgG or mB7H4 Ig
(10 	g/ml). Cells were harvested at the indi-
cated times and analyzed using flow cy-
tometry.
(B) CD4 T cells were purified from pools of
spleens and lymph nodes of BALB/c using
magnetic selection column and subsequently
added at 3 
 105/well, which were coated
with anti-CD3 mAb (3 	g/ml) and mB7H4 Ig
or control IgG (10 	g/ml). After 48 hr of incu-
bation, cells were pulsed with 10 	M BrdU
for 1 hr, subsequently harvested, and stained
with FITC-conjugated anti-BrdU and 7-AAD.
Cells were subjected to FACS analysis. The
results are representative of three indepen-
dent experiments.
alloreactive CTL activity significantly in comparison with tion, we also found that a genomic DNA sequence
that by control hamster Ig. CTL activity was specific for (FLJ22418) containing an entire open reading frame for
P815 (H-2d) but not for syngeneic EL4 cells (Figure 7C). human B7-H4 was deposited in GenBank recently.
Our results indicate that blockade of endogenous B7- Several lines of evidence support B7-H4’s role in neg-
H4 on host cells promotes the generation of allogeneic ative regulation of T cell responses. Immobilized B7-H4
CTL. Taken together, our data support the role of endog- inhibited T cell growth and cytokine secretion. More-
enous B7-H4 in the inhibition of cell-mediated immunity. over, administration of B7-H4Ig led to inhibition of T cell
proliferation and cytolytic activity against allogeneic an-
tigens in vivo. Although these experiments could beDiscussion
interpreted as an agonistic effect of B7-H4 on its recep-
tor, they do not exclude the possibility that B7-H4Ig alsoSimilar to the other B7 family molecules, B7-H4 shares
blocked the interaction between B7-H4 and its putative20%–25% amino acid identity to other members and
receptor on T cells. However, expression of membrane-contains both the IgV and IgC domain in its extracellular
bound, but not soluble form, B7-H4 on EL4 cells alsoregion. Sequence analysis and computer modeling re-
inhibits proliferation of CD8 T cells and developmentveal structural similarity of B7-H4 to the other B7 family
of CTL activity. Consistent with this experiment, block-members. These features clearly place B7-H4 as a mem-
ade of B7-H4 by mAbs that block the inhibitory effectber of the B7 family. Many B7-like proteins have been
of B7-H4 in vitro (Figure 5D), promoted the inductionpredicted by simple homology search and alignment
of allogeneic CTL in vivo. Taken together, our resultsanalysis (Fahrer et al., 2001). These molecules often,
support a role of endogenous B7-H4 on host cells inhowever, lack critical signature amino acids and struc-
inhibiting T cell responses.tural features of the B7 family. In our study, a combina-
Our results indicate that B7-H4 inhibits T cell re-tion of primary sequence homology and structural analy-
sponses by cell cycle arrest whereas its effect on T cellsis is critical for preliminary identification of B7-H4.
apoptosis is minimal. This finding supports the notionFACS analysis using hH4 mAb indicate that B7-H4 does
that the effect of B7-H4 is on a relatively early stage ofnot constitutively express on peripheral tissues but
T cell activation and explains the nonselective effectcould be induced to express on human T, B, macro-
of B7-H4 on the inhibition of cytokine production. Thephages, and DC. In a recent homology search in the
inhibitory effects of B7-H4 on T cell proliferation and IL-2NCBI and Celera databases, we found that the highest
homologous sequences are B7-H1 and B7-H3. In addi- secretion could only be partially reversed by increased
Immunity
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Figure 7. B7-H4 Inhibits T Cell Responses In
Vivo
(A) B6 mice were i.v. given 1 
 107 spleen
cells from OT-1 mouse and subsequently
challenged with 500 	g of OVA peptide i.v.
for activation of OT-1 T cells. mB7H4Ig or
control IgG were given i.p. on day 0 (250 	g)
and day 3 (100 	g). On day 6, spleen cells
were prepared and doubly stained with OVA/
tetramer and anti-CD8 mAb for FACS analy-
sis. The mice, which were infused with OT-1
T cells but were not challenged with OVA pep-
tide (None), were used as additional control.
The results are representative of four inde-
pendent experiments.
(B) BDF1 mice, in groups of two or three, were
given i.v. 5 
 107 splenocytes from B6 mice
as described previously (Tamada et al., 2000,
2002). On day 0 (150 	g), day 3 (100 	g), and
day 6 (100 	g), mB7H4Ig or control IgG were
injected i.p. On day 10, recipient splenocytes
were prepared and, without further in vitro
stimulation, cocultured with 51Cr-labeled
P815 (H-2d) and EL-4 (H-2b) at the indicated
E:T ratios for 4 hr. Released 51Cr was mea-
sured in a Microbeta TriLux liquid scintillation
counter (Wallac, Finland). The data from two
individual mice are presented, and the results
are representative of three independent ex-
periments.
(C) BDF1 mice were given 5 
 107 B6 spleen
cells and 200 	g of control hamster IgG or
8H4 mAb via tail vein on day 0. Each antibody
at 100 	g was injected subsequently on days
2, 4, and 6. On day 10, CTL activity of recipient
splenocytes was measured against P815
(H-2d) or EL4 (H-2b) cells in the indicated ef-
fector:target cell ratios in 4 hr 51Cr-release
assay as described in (B). The results are rep-
resentative of three independent experi-
ments.
costimulation through CD28 signal, indicating that B7- teresting to determine whether B7-H4 inhibition is also
mediated in a fashion similar to the CTLA-4 pathwayH4 is a potent attenuator of T cell responses. It has
been shown that CTLA-4 signaling arrests cell cycle and the relationship between these two pathways.
In summary, B7-H4 has a profound effect on the inhibi-progression (Krummel and Allison, 1996) and inhibits
T cell receptor signaling by recruiting SHP-2 (Lee et al., tion of T cell responses at a relatively early stage. There-
fore, engagement of early primed T cells by B7-H4 con-1998; Marengere et al., 1996). Similar to the inhibitory
activity of the putative receptor for B7-H4, CTLA-4 inhib- stitutes a checkpoint in negative control of T cell
activation. Together with a broad and inducible expres-its TCR-induced T cell proliferation and IL-2 production
(Salomon and Bluestone, 2001). Therefore, it will be in- sion pattern, B7-H4 may be involved in attenuation of
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RNA Analysisinflammatory responses on peripheral tissues. Further
Human and mouse multiple tissue mRNA for Northern blots andcharacterization of the B7-H4 pathway thus provides a
cDNA panels (Clontech, CA) for PCR analysis of B7-H4 expressionnew opportunity for manipulation of cell-mediated im-
were performed according to the manufacturer’s instructions (Dong
mune responses in cancers, autoimmune diseases, viral et al., 1999). Human B7-H4 was amplified with forward primer (5-GAG
infection, and transplantation rejection. ATCAAAAGGCGGAGTCACCTACAGCTGC-3) and reverse primer
(5-GCTCCCCTCTTTCCAGGCCCTTTTCTACTC-3) binding to the
transmembrane domain and 3 UTR of hB7-H4, respectively. For
Experimental Procedures
amplification of mouse B7-H4, two primers (forward primer, 5-GGC
ATTTCAGGCAAGCACTTC-3; reverse primer, 5-GCCTCGCAGCG
Bioinformatics and Molecular Cloning
TAAACTCTCT-3) covering the extracellular domain were used. For
Human B7-H4 was originally identified from the NCBI database
RT-PCR analysis, adherent cells were harvested by trypsin EDTA
based on homology to other B7 family molecules. Full-length human
(Mediatech, VA), and RNA was isolated using the Qiagen RNeasy
B7-H4 cDNA was amplified by PCR with PFU polymerase (Stra-
kit (Qiagen, CA) from cytoplasmic cell fractions. All RNA samples
tagene, CA) from human placental cDNA (Clontech, CA), cloned
were digested with DNase I (Qiagen). Total RNA was reverse tran-
into pcDNA 3.1 vector (Invitrogen, CA), and confirmed by DNA
scribed with Superscript II RT using random hexamers, and PCR
sequencing. To isolate mouse B7-H4 homolog, several sets of prim-
was performed using the same primers indicated to detect B7-H4.
ers based on mouse and human EST sequences were used to am-
plify mouse B7-H4 cDNA from spleen cDNA of a C57BL/6 (B6)
Cell Linesmouse. Full-length mouse B7-H4 cDNA was similarly cloned into
P815 mouse mastocytoma, B7-1.P815, B7-H1.P815 (Dong et al.,pcDNA 3.1 vector and confirmed by DNA sequencing. Fusion pro-
2002), human 293T cells, and human B7-H2.CHO line (Wang et al.,tein constructs of human B7-H4, mouse B7-H4, and mouse B7-1
2000) were described previously. Human peripheral blood mononu-were prepared by cloning the extracellular domain of B7-H4 or B7-1
clear cells (PBMC) were prepared by density gradient centrifugationin-frame with the hinge-CH2-CH3 domain of either human IgG1 or
over Ficoll-Paque plus (Pharmacia, NJ). EL4 lines transfected withmouse IgG2a (Chapoval et al., 2002). To enhance the secretion of
the plasmids containing neomycin-resistant gene (mock.EL4) orfusion protein, the native signal peptide of B7-H4 was replaced with
mouse B7-H4 cDNA (EmH4) were established by neomycin selectionthe preprotrypsin signal peptide derived from pCMV FLAG vector
and cell cloning. EG7 is an EL4 transfectant expressing chicken(Sigma, MO).
ovalbumin (OVA) protein. Human DC were prepared from plastic
adherent PBMC in the presence of IL-4 and GM-CSF (Chapoval et
Molecular Modeling al., 2000). Human aortic endothelium cells (gift of Dr. Jeffrey Platt)
Molecular models of the N-terminal V domains of human and mouse were stimulated overnight with 10 ng/ml TNF- or 1500 IU/ml IFN-
B7-H4 were built by homology modeling based on the X-ray struc- (R&D, MN). Human and mouse T cells were purified by nylon wool
tures of human CD80 and CD86 (Stamper et al., 2001; Schwartz et column and magnetic activated cell sorting separation column. The
al., 2001) using MOE (Molecular Operating Environment, Chemical purity of the CD4 cells from DO11.10 TCR transgenic T cells
Computing Group, Quebec, Canada). Insertions and deletions in was 99%. For flow cytometry analysis, cells were stained with 10
mouse and human B7-H4 relative to the structural template(s) were 	g of fusion protein or the indicated mAb for 30 min at 4C. Fc
modeled employing a protein database segment matching proce- receptors were blocked with anti-FcR (clone 2.4G2, ATCC) for 15
dure (Levitt, 1992; Fechteler et al., 1995) implemented in MOE. Side min at 4C prior to staining. Cells were then washed extensively and
chain replacements were carried out using a rotamer library (Ponder further incubated with secondary mAb.
and Richards, 1987) extracted from high-resolution protein data-
bank structures (Berman et al., 2000). Intramolecular contacts and In Vitro Analysis of T Cell Responses
stereochemistry of the models were optimized by limited energy For T cell proliferation assays, 96-well flat bottom plates were coated
minimization using protein force field parameters (Engh and Huber, with varying concentrations of anti-CD3 mAb (clone 500A2, Phar-
1991). Residue mapping studies and computer graphical analyses mingen, CA) in PBS at 4C overnight. Wells were washed extensively
were carried out with InsightII (MSI, CA). and coated with 10 	g/ml of the indicated fusion protein for 2 hr at
37C. When two different fusion proteins were plated, they were
mixed together, each at a concentration of 10 	g/ml in PBS, priorTransfection
to plating. Wells were washed extensively and plated with purifiedTo produce human or mouse B7-H4Ig, 293T cells were transfected
CD4 DO11.10 cells at 1.5 
 106 cells/ml. Alternatively, mock.EL4with 10 	g of mouse or human B7-H4Ig constructs by the calcium
or EmH4 cells were -irradiated (26,000 rad) and further incubatedphosphate method and B7-H4Igs were purified from culture super-
overnight with 10 	g/ml of SIINFEKL peptide. The peptide-pulsednatant by protein G column as described previously (Dong et al.,
cells at 6 
 104/well were cocultured with 3 
 105 OT-1 T cells/well,1999). Stable 293T cell lines expressing human and mouse B7-
incubated for 72 hr, and pulsed with 1 	Ci of [3H]thymidine (TdR).H4 or mock-transfected lines were prepared by cotransfection of
For measurement of cytolytic activity of OT-1 cells, -irradiated andpcDNA vector containing human or mouse B7-H4 cDNA with
peptide-pulsed EL4 transfectants at 3
 105/well were cultured withpLXSHD, a plasmid encoding histidinol-resistant gene (a gift from
purified OT-1 cells at 1.5 
 106/well in 24-well plates. On day 4, OT-1Dr. Dusty Miller). Stable clones were selected with 20 mM histidinol
T cells were purified by Lympholyte-M (Cedarlane, Canada) and(Sigma, MO). Clones expressing B7-H4 were screened with human
incubated at the indicated effector:target ratios with 51Cr-labeledor mouse B7-H4 mAb, respectively.
EG7 or P815 cells for 4 hr (Wilcox et al., 2002).
For cell division measurement, naive T cells were purified from
spleens and lymph nodes of B6 mice using nylon wool column,Preparations of Monoclonal Antibodies
The method for the generation of mAb to mouse and human B7-H4 labeled with CFSE (Molecular Probes, Eugene, OR) according to
the manufacturer’s instructions, and analyzed by flow cytometry.by immunization of an Armenian hamster and a BALB/c mouse,
respectively, were described previously (Wilcox et al., 2002). Two For cell cycle analysis, CD4 T cells were activated by anti-CD3
mAb plus 10 	g/ml control IgG or mB7H4Ig for 48 hr. Cells wereindependent clones, 8H4 and 8H4.1, which secret hamster mAb
(IgG) against mouse B7-H4, and clone hH4, which secretes mouse incubated with bromodeoxyuridine (BrdU) at 10 	M for 1 hr at 37C.
Staining of incorporated BrdU was performed using reagents frommAb (IgG1) against human B7-H4, were selected, and mAbs were
purified by IgG affinity column. Specificity of the mAb was deter- the BrdU Flow Kit (BD Bioscience, San Diego, CA), according to the
manufacturer’s instructions. Cells were stained with FITC-conju-mined by negative staining of various transfectants expressing B7
family molecules including B7-1, B7-2, B7-H1, B7-DC, B7-H2, and gated anti-BrdU antibody for 20 min at room temperature. Twenty
	g/ml 7-amino-actinomycin D (7-AAD) was added to cell suspensionB7-H3. Control hamster IgG and mouse IgG1 were purchased from
Rockland (Gilbertville, PA). A hamster IgG mAb against DNP (clone before flow cytometry analysis.
All primary mouse T cells and transfectants were grown in RPMIUC8-1B9, ATCC) was also used as the control.
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1640-based T cell media supplemented with 2-mercaptoethanol associated B7-H1 promotes T-cell apoptosis: a potential mecha-
nism of immune evasion. Nat. Med. 8, 793–800.(Gibco BRL, MD). Sandwich ELISA for indicated cytokines was per-
formed according to the manufacturer’s instructions (Pharmin- Engh, R.A., and Huber, R. (1991). Accurate bond and angle parame-
gen, CA). ters for X-ray protein structure refinement. Acta Crystallogr. A 47,
392–400.
Animal Studies
Fahrer, A.M., Bazan, J.F., Papathanasiou, P., Nelms, K., and Good-
Spleen cells from OT-1 mouse (H-2b) were prepared and suspended
now, C.C. (2001). A genomic view of immunology. Nature 409,
in Hanks’ balanced salt solution (HBSS) and transferred into sex-
836–838.
matched naive B6 mice (H-2b) by tail vein injection (1 
 107 cells/
Fechteler, T., Dengler, U., and Schomburg, D. (1995). Predictionmouse). Two days later (day 0), recipients were challenged by i.v.
of protein three-dimensional structures in insertion and deletioninjection of 500 	g of SIIN peptide. Control IgG or mB7H4Ig was
regions: a procedure for searching databases of representative pro-given i.p. on day 0 (250 	g) and day 3 (100 	g). On day 6, recipient
tein fragments using geometric scoring criteria. J. Mol. Biol. 253,spleen cells were prepared and doubly stained with MHC class
114–131.I/peptide tetramers of H-2Kb/SIINFEKL (NIH tetramer core facility,
Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishi-Emory University, GA) and anti-CD8 mAb (Pharmingen, San Diego,
mura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., et al.CA) to identify the OT-1 TCR transgenic T cells by flow cytometry
(2000). Engagement of the PD-1 immunoinhibitory receptor by a(Beckman Coulter, San Diego, CA).
novel B7 family member leads to negative regulation of lymphocytePrimary allogeneic CTL in a graft versus host disease setting were
activation. J. Exp. Med. 192, 1027–1034.generated by injection i.v. of 5 
 107 purified splenocytes from
B6 mice into 5-week-old BDF1 mice (Tamada et al., 2000, 2002). Grimbacher, B., Hutloff, A., Schlesier, M., Glocker, E., Warnatz, K.,
Recipients were also given i.p. control IgG or mB7H4Ig on day 0 Drager, R., Eibel, H., Fischer, B., Schaffer, A.A., Mages, H.W., et al.
(150 	g), day 3 (100 	g), and day 6 (100 	g). In some experiments, (2003). Homozygous loss of ICOS is associated with adult-onset
recipients were injected with 100 	g 8H4 mAb or control hamster common variable immunodeficiency. Nat. Immunol. 4, 261–268.
IgG at days 0, 2, 4 and 6. On day 10, CTL activity of recipient Hurwitz, A.A., Kwon, E.D., and van Elsas, A. (2000). Costimulatory
splenocytes was determined using standard 4 hr 51Cr release assay wars: the tumor menace. Curr. Opin. Immunol. 12, 589–596.
by coculturing with 51Cr-labeled P815 (H-2d) or EL4 (H-2b) at the
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Accession Numbers
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